New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
December 19, 2018 - The FDA announced the approval of IBSA Pharma’s Licart (diclofenac epolamine), for the topical treatment of acute pain due to minor strains, sprains, and contusions.
Download PDF
Return to publications
